Xanodyne Pharmaceuticals, Inc. announced that it has received agree to from the U.S. Food and Pharmaceutical Charge (FDA) for Zipsor (diclofenac potassium) Liquid Filled Capsules, a unfamiliar treatment option indicated for relief of mild to moderate acute pain in adults (18 years of age or older).

“Zipsor is a soporific with several unexcelled features,” said Gary A. Shangold, Chief Medical Policewoman of Xanodyne. “It is the principal NSAID to be approved based on the demonstration of safety and efficacy in two proficiently controlled post-surgical bunionectomy clinical trials and accomplished this with the lowest available dose (25 mg) of any currently marketed diclofenac potassium product in the Harmonious States. It will also be the beginning and solitary prescription muscle NSAID an eye to uttered distribution accessible for the U.S. market in a liquid-filled cushion gelatin capsule,” continued Dr. Shangold.

The substandard recommended mount up to common dose of diclofenac potassium delivered with Zipsor aligns with simultaneous control from the FDA recommending utilization of NSAIDs at the lowest effective administer, notwithstanding the shortest amount of time. Zipsor was generally well-tolerated and demonstrated efficacy in two multiple dosage post-surgery (bunionectomy) clinical trials. At baseline, Zipsor patients had an average pain intensity of 6.9 (on a 0 to 10 numeric despair rating scale).

“Demonstrating efficacy at a indelicate dose not previously available to the bazaar presents an notable new restorative recourse to the physician and a significant opportunity for Xanodyne. It is also a pregnant milestone for our company as Zipsor represents the first authorization to come out of our R&D organization. We are completing our start preparations and our outlook is to have Zipsor on the US exchange within the coming months,” said Michael Valentino, President and Chief Executive Old Bill.

Formidable Sanctuary Gen adjacent to Zipsor

Like all prescription non-steroidal anti-inflammatory drugs (NSAIDs), Zipsor may increase the chance of a heart condemn or stroke that can lead to death. Zipsor should not be worn opportunely rather than or after certain humanitarianism surgeries. Unsmiling scrape reactions or stomach and intestine problems, such as bleeding and ulcers, can occur without caveat and may cause death. Patients winning aspirin or other blood thinners and the elderly are at increased risk fitting for stomach bleeding and ulcers. Tell your doctor involving all of the medications you assume and all of your medical conditions prior to fascinating Zipsor, especially if you are pregnant, have a history of ulcers or bleeding in the stomach or intestines, secure anticyclone blood make or verve failure or core disease, or have kidney or liver problems. People with aspirin-sensitive asthma or allergic reactions due to aspirin or other NSAIDs should not take Zipsor. Prescription Zipsor should be used absolutely as prescribed at the lowest reasonable portion for the shortest time needed. For additional high-ranking information about Zipsor see the FDA-approved medication guide or the full prescribing information.

About Xanodyne

Xanodyne Pharmaceuticals, Inc., which commenced operations in 2001, is an integrated specialty pharmaceutical group with both development and commercial capabilities focused on women’s healthcare and grief management. Xanodyne markets a portfolio of net income generating products consisting of prescription pharmaceuticals and a line of prenatal vitamins. Additionally, Xanodyne is advancing a dilatory stage pipeline of product candidates targeted at expressive what it takes markets in Xanodyne’s focus areas.

Source: Xanodyne Pharmaceuticals, Inc